Folic/folinic acid

DRUG4 trials

Sponsors

Sanofi, Takeda, University of British Columbia

Conditions

Juvenile Idiopathic ArthritisRheumatoid ArthritisUveitis

Phase 2

Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers

TerminatedNCT01217814

SanofiRheumatoid Arthritis

Start: 2010-11-30End: 2011-09-30Updated: 2017-09-01

Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis

CompletedNCT01900431

Start: 2013-10-31End: 2016-04-30Updated: 2017-06-20

Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA)

CompletedNCT02379091

TakedaRheumatoid Arthritis

Start: 2014-12-17End: 2016-12-05Updated: 2018-09-14

Unknown Phase

The Ondansetron Premedication Trial in Juvenile Idiopathic Arthritis

CompletedNCT04169828

University of British ColumbiaJuvenile Idiopathic Arthritis

Start: 2019-08-02End: 2025-01-17Updated: 2025-06-29

Related Papers

Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis

Lara D. Veeken2023-02-0211 citations

Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial.

2019-04-1868 citations

Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody.

2018-11-0231 citations

Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis

Arthritis Research & Therapy2017-03-0835 citations